jcm-logo

Journal Browser

Journal Browser

Clinical Management of Bladder Cancer

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".

Deadline for manuscript submissions: 20 December 2025 | Viewed by 351

Special Issue Editors


E-Mail Website
Guest Editor
Department of Urology, Azienda Ospedaliera Universitaria Sant'Andrea, Sapienza, Università di Roma, Rome, Italy
Interests: surgery; prostate cancer; robotics; bladder cancer; minimally invasive surgery

E-Mail
Guest Editor
Department of Urology, Azienda Ospedaliera Universitaria Sant'Andrea, Sapienza, Università di Roma, Rome, Italy
Interests: prostate cancer; IPB; robotic surgery; bladder cancer; endourology

E-Mail
Guest Editor
Department of Urology, University of Verona, Verona, Italy
Interests: surgery; kidney cancer; robotics; bladder cancer; minimally invasive surgery

Special Issue Information

Dear Colleagues,

Bladder cancer remains a significant global health challenge, with its incidence and mortality rates necessitating continuous advancements in diagnosis, treatment, and long-term management. Recent innovations in surgical techniques, systemic therapies, and personalized medicine have reshaped the therapeutic landscape, improving survival outcomes and quality of life for patients. This Special Issue will provide a comprehensive overview of the latest developments in bladder cancer treatment and management, covering topics such as minimally invasive surgery, novel immunotherapeutic and targeted approaches, biomarkers for disease stratification, and advancements in imaging and diagnostics. Additionally, we welcome contributions discussing multidisciplinary strategies, clinical decision-making in muscle-invasive and non-muscle-invasive bladder cancer, and long-term surveillance protocols. By gathering original research, systematic reviews, and clinical perspectives, this Special Issue will enhance understanding of evidence-based and emerging therapeutic approaches, ultimately improving patient care. We invite researchers, clinicians, and specialists in urology, oncology, pathology, and related fields to contribute their latest findings and insights.

Dr. Antonio Franco
Dr. Antonio Cicione
Dr. Francesco Ditonno
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bladder cancer
  • minimally invasive surgery
  • immunotherapy
  • targeted therapy
  • biomarkers
  • imaging techniques
  • muscle invasive bladder cancer
  • non-muscle-invasive bladder cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

27 pages, 1266 KiB  
Systematic Review
Genotoxicity Induced by Carcinogenic Agents or Occupational Exposure with Sufficient Evidence for Bladder Cancer
by Edyta Kasperczyk, Kateryna Tarhonska and Ewa Jablonska
J. Clin. Med. 2025, 14(13), 4492; https://doi.org/10.3390/jcm14134492 - 25 Jun 2025
Viewed by 279
Abstract
Background: There is substantial evidence supporting the role of genetic alterations in chemically induced carcinogenesis. We analyzed the existing literature to gather data on genetic alterations linked to human carcinogens and their possible connection to genotoxic outcomes. The review emphasizes carcinogenic substances [...] Read more.
Background: There is substantial evidence supporting the role of genetic alterations in chemically induced carcinogenesis. We analyzed the existing literature to gather data on genetic alterations linked to human carcinogens and their possible connection to genotoxic outcomes. The review emphasizes carcinogenic substances and occupational exposures identified as “carcinogenic to humans”. In particular, we searched for studies describing genotoxic alterations linked to agents and occupational exposures for which the International Agency for Research on Cancer has found sufficient evidence of an association with bladder cancer. Methods: The review was carried out in compliance with the PRISMA standards. A comprehensive search of the PubMed database was conducted to identify studies published through March 2024. Results: We identified 60 studies that evaluated genetic alterations for 16 carcinogenic agents and occupations (such as aluminum production, 4-aminobiphenyl, auramine production, benzidine, chlornaphazine, cyclophosphamide, firefighters, magenta production, 2-naphthylamine, opium consumption, ortho-toluidine, painters, the rubber manufacturing industry, Schistosoma haematobium infection, X-radiation, gamma-radiation) in healthy humans. Conclusions: The genotoxic effects of chemical agents in healthy individuals have been well studied and characterized. Additionally, this review presents numerous studies concerning occupational exposure but not exclusively. Genotoxicity assessments have mainly been conducted on biological materials such as blood, peripheral blood lymphocytes, urine, and buccal epithelial cells. The most frequently examined genotoxic effects were DNA damage, chromosomal abnormalities, and micronuclei. Standardized data to clearly define a dose–response relationship for predicting delayed health effects are still lacking. Full article
(This article belongs to the Special Issue Clinical Management of Bladder Cancer)
Show Figures

Figure 1

Back to TopTop